2016
DOI: 10.3233/jad-150972
|View full text |Cite
|
Sign up to set email alerts
|

Bridging Integrator 1 (BIN1) Genotypes Mediate Alzheimer’s Disease Risk by Altering Neuronal Degeneration

Abstract: This study supported that BIN1 contributes to the risk of AD by altering neural degeneration (abnormal tau, brain atrophy and glucose metabolism) but not Aβ pathology.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

4
31
0

Year Published

2016
2016
2024
2024

Publication Types

Select...
10

Relationship

2
8

Authors

Journals

citations
Cited by 40 publications
(35 citation statements)
references
References 44 publications
4
31
0
Order By: Relevance
“…As reported in previous studies, although some progressive brain tissue atrophies occurred with normal aging, these atrophies were greatly accelerated in AD patients [41,42]. These domains, which included the hippocampus, entorhinal cortex and middle temporal lobe were explored in this analysis.…”
Section: Mri Scans and Image Processingmentioning
confidence: 97%
“…As reported in previous studies, although some progressive brain tissue atrophies occurred with normal aging, these atrophies were greatly accelerated in AD patients [41,42]. These domains, which included the hippocampus, entorhinal cortex and middle temporal lobe were explored in this analysis.…”
Section: Mri Scans and Image Processingmentioning
confidence: 97%
“…The recent identification of Bin1 as a FEME component [28] broadens the possibilities for a link between FEME and neurodegeneration. Bin1 is strongly linked to Alzheimer's disease, but through Tau and amyloid-β pathology [122,123]. As for Endophilin, Bin1 levels are increased in Alzheimer's patients and its depletion suppressed Tau-mediated neurotoxicity [124].…”
Section: Is Feme Involved In Neurodegenerative Diseases?mentioning
confidence: 99%
“…AD is a clinically heterogeneous neurodegenerative disease with a strong genetic component. Genetic risk factors of AD impact the CSF or neuroimaging biomarkers through which they might modulate the process of AD [ 5 ]. Thus, biomarkers for AD may be used as endophenotypes to explore the genetic factors that impact their metabolism [ 6 8 ].…”
Section: Introductionmentioning
confidence: 99%